Ordered Items: **NMR LipoProfile+Lipids+Graph; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Iron and TIBC; Testosterone Free, Profile I; Apo A1 + B + Ratio; Vitamin B12 and Folate; Hemoglobin A1c; Thyroxine (T4) Free, Direct; Cortisol; TSH; Prostate-Specific Ag; Vitamin D, 25-Hydroxy; C-Reactive Protein, Cardiac; Methylmalonic Acid, Serum; Homocyst(e)ine; Uric Acid; Phosphorus; Sedimentation Rate-Westergren; Bilirubin, Direct; Magnesium; Insulin; Ferritin; Triiodothyronine (T3), Free**

Date Collected: **08/07/2025**

NMR LipoProfile+Lipids+Graph

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
LDL Particle Number [01]				
LDL-P [A, 01]	452	559 04/02/2025	nmol/L	<1000
Lipids [01]				
LDL-C (NIH Calc) [01]	42	54 04/02/2025	mg/dL	0-99
HDL-C [A, 01]	54	41 04/02/2025	mg/dL	>39
Triglycerides [A, 01]	49	78 04/02/2025	mg/dL	0-149
Cholesterol, Total [A, 01]	108	111 04/02/2025	mg/dL	100-199
LDL and HDL Particles [01]				
HDL-P (Total) [A, 01]	30.7	**28.5** 04/02/2025	umol/L	>=30.5
Small LDL-P [A, 01]	225	324 04/02/2025	nmol/L	<=527
LDL Size [A, 01]	20.8	**20.4** 04/02/2025	nm	>20.5

```
LDL-P
Low                    < 1000
Moderate          1000 - 1299
Borderline-High   1300 - 1599
High              1600 - 2000
Very High              > 2000

LDL-C (NIH Calc)
Optimal                <  100
Above optimal      100 -  129
Borderline         130 -  159
High               160 -  189
Very high              >  189
```

```
----------------------------------------------------------
               ** INTERPRETATIVE INFORMATION**
               PARTICLE CONCENTRATION AND SIZE
                  <--Lower CVD Risk   Higher CVD Risk-->
 LDL AND HDL PARTICLES   Percentile in Reference Population
 HDL-P (total)        High     75th    50th    25th    Low
                      >34.9    34.9    30.5    26.7    <26.7
 Small LDL-P          Low      25th    50th    75th    High
                      <117     117     527     839     >839
 LDL Size   <-Large (Pattern A)->    <-Small (Pattern B)->
                   23.0    20.6          20.5      19.0
----------------------------------------------------------
```

Comment: [01]

```
Small LDL-P and LDL Size are associated with CVD risk, but not after
LDL-P is taken into account.
```

Insulin Resistance Score [01]				
LP-IR Score [A, 01]	35	27 04/02/2025		<=45

```
INSULIN RESISTANCE MARKER
    <--Insulin Sensitive    Insulin Resistant-->
           Percentile in Reference Population
```


©2025 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 800-282-7300

NMR LipoProfile+Lipids+Graph (Cont.)

	Insulin Resistance Score					
	LP-IR Score	Low	25th	50th	75th	High
		<27	27	45	63	>63
Comment: [01]	LP-IR Score is inaccurate if patient is non-fasting. The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.					
PDF [01]	.			.	04/02/2025	
Historical Reporting [01]	Comment:			Comment:	04/02/2025	

Collection Date	LDL-P	LDL-C
08/07/2025	452	42
04/02/2025	559	54
10/30/2024	756	70

CBC With Differential/Platelet

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
WBC [02]	4.2	5.0	06/02/2025	x10E3/uL	3.4-10.8
RBC [02]	5.34	5.58	06/02/2025	x10E6/uL	4.14-5.80
Hemoglobin [02]	14.6	14.6	06/02/2025	g/dL	13.0-17.7
Hematocrit [02]	46.4	47.4	06/02/2025	%	37.5-51.0
MCV [02]	87	85	06/02/2025	fL	79-97
MCH [02]	27.3	**26.2**	06/02/2025	pg	26.6-33.0
MCHC [02]	31.5	**30.8**	06/02/2025	g/dL	31.5-35.7
RDW [02]	14.4	15.0	06/02/2025	%	11.6-15.4
Platelets [02]	191	210	06/02/2025	x10E3/uL	150-450
Neutrophils [02]	63	65	06/02/2025	%	Not Estab.
Lymphs [02]	26	23	06/02/2025	%	Not Estab.
Monocytes [02]	8	8	06/02/2025	%	Not Estab.
Eos [02]	3	4	06/02/2025	%	Not Estab.

©2025 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 800-282-7300

CBC With Differential/Platelet (Cont.)

Basos [02]	0	0	06/02/2025	%	Not Estab.
Neutrophils (Absolute) [02]	2.6	3.2	06/02/2025	x10E3/uL	1.4-7.0
Lymphs (Absolute) [02]	1.1	1.2	06/02/2025	x10E3/uL	0.7-3.1
Monocytes(Absolute) [02]	0.4	0.4	06/02/2025	x10E3/uL	0.1-0.9
Eos (Absolute) [02]	0.1	0.2	06/02/2025	x10E3/uL	0.0-0.4
Baso (Absolute) [02]	0.0	0.0	06/02/2025	x10E3/uL	0.0-0.2
Immature Granulocytes [02]	0	0	06/02/2025	%	Not Estab.
Immature Grans (Abs) [02]	0.0	0.0	06/02/2025	x10E3/uL	0.0-0.1

Comp. Metabolic Panel (14)

	Test	Current Result and Flag		Previous Result and Date		Units	Reference Interval
▼	**Glucose** [02]	**68**	**Low**	70	06/02/2025	mg/dL	70-99
▲	**BUN** [02]	**25**	**High**	24	06/02/2025	mg/dL	6-24
	Creatinine [02]	0.82		0.92	06/02/2025	mg/dL	0.76-1.27
	eGFR	106		101	06/02/2025	mL/min/1.73	>59
▲	**BUN/Creatinine Ratio**	**30**	**High**	**26**	06/02/2025		9-20
	Sodium [02]	140		141	06/02/2025	mmol/L	134-144
	Potassium [02]	4.2		4.1	06/02/2025	mmol/L	3.5-5.2
	Chloride [02]	102		101	06/02/2025	mmol/L	96-106
	Carbon Dioxide, Total [02]	22		23	06/02/2025	mmol/L	20-29
	Calcium [02]	9.1		9.1	06/02/2025	mg/dL	8.7-10.2
	Protein, Total [02]	6.6		6.7	06/02/2025	g/dL	6.0-8.5
	Albumin [02]	4.5		4.6	06/02/2025	g/dL	3.8-4.9
	Globulin, Total	2.1		2.1	06/02/2025	g/dL	1.5-4.5
	Bilirubin, Total [02]	0.7		0.4	06/02/2025	mg/dL	0.0-1.2
	Alkaline Phosphatase [02]	56		66	06/02/2025	IU/L	44-121
	AST (SGOT) [02]	25		18	06/02/2025	IU/L	0-40
	ALT (SGPT) [02]	20		18	06/02/2025	IU/L	0-44

Iron and TIBC

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Iron Bind.Cap.(TIBC)	329	340	06/02/2025	ug/dL	250-450
UIBC [02]	250	296	06/02/2025	ug/dL	111-343
Iron [02]	79	44	06/02/2025	ug/dL	38-169
Iron Saturation	24	**13**	06/02/2025	%	15-55

Testosterone Free, Profile I

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Testosterone [02]	516	353	06/02/2025	ng/dL	264-916
	Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.				
Sex Horm Binding Glob, Serum [02]	44.6	38.7	06/02/2025	nmol/L	19.3-76.4

©2025 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 800-282-7300

Testosterone Free, Profile I (Cont.)

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Testost., Free, Calc	88.0	57.4	10/30/2024	pg/mL	35.8-168.2

Apo A1 + B + Ratio

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Apolipoprotein A-1 [01]	142	126	04/02/2025	mg/dL	101-178
Apolipoprotein B [01]	44	50	06/02/2025	mg/dL	<90

```
                    Desirable                 < 90
                    Borderline High       90 -  99
                    High                 100 - 130
                    Very High               >130
--------------------------------------------------
      ASCVD RISK                 THERAPEUTIC TARGET
       CATEGORY                     APO B (mg/dL)
  Very High Risk          <80 (if extreme risk <70)
  High Risk               <90
  Moderate Risk           <90
```

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Apolipo. B/A-1 Ratio	0.3	0.4	04/02/2025	ratio	0.0-0.7

```
Apolipoprotein B/A-1 Ratio
                 Male  Female
    Avg.Risk     0.7    0.6
  2X Avg.Risk    0.9    0.9
  3X Avg.Risk    1.0    1.0
```

Vitamin B12 and Folate

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Vitamin B12 [02]	823	840	06/02/2025	pg/mL	232-1245
Folate (Folic Acid), Serum [02]	18.1	11.3	06/02/2025	ng/mL	>3.0

Note: [02]

A serum folate concentration of less than 3.1 ng/mL is considered to represent clinical deficiency.

Hemoglobin A1c

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Hemoglobin A1c [02]	5.2	5.3	06/02/2025	%	4.8-5.6

Please Note: [02]

```
Prediabetes: 5.7 - 6.4
Diabetes: >6.4
Glycemic control for adults with diabetes: <7.0
```

Thyroxine (T4) Free, Direct

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
T4,Free(Direct) [02]	1.65	1.46	04/02/2025	ng/dL	0.82-1.77

Cortisol

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Cortisol [02]	10.9	13.1	04/02/2025	ug/dL	6.2-19.4

Please Note: The reference interval and flagging for

©2025 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 800-282-7300

Cortisol (Cont.)

this test is for an AM collection. If this is a PM collection please use: Cortisol PM: 2.3-11.9

TSH

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
TSH [02]	0.929	1.800	06/02/2025	uIU/mL	0.450-4.500

Prostate-Specific Ag

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Prostate Specific Ag [02]	0.9		ng/mL	0.0-4.0

Roche ECLIA methodology.
According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.
Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Vitamin D, 25-Hydroxy

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Vitamin D, 25-Hydroxy [02]	50.8	54.2	06/02/2025	ng/mL	30.0-100.0

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).

1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

C-Reactive Protein, Cardiac

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
C-Reactive Protein, Cardiac [02]	0.92	1.96	06/02/2025	mg/L	0.00-3.00

Relative Risk for Future Cardiovascular Event	
Low	<1.00
Average	1.00 - 3.00
High	>3.00

Methylmalonic Acid, Serum

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Methylmalonic Acid, Serum [A, 01]	98	108	04/02/2025	nmol/L	0-378

©2025 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 800-282-7300

Date Collected: **08/07/2025**

Homocyst(e)ine

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Homocyst(e)ine [02]	13.8	13.0	06/02/2025	umol/L	0.0-14.5

Uric Acid

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Uric Acid [02]	4.8	4.7	06/02/2025	mg/dL	3.8-8.4
		Therapeutic target for gout patients: <6.0			

Phosphorus

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Phosphorus [02]	2.9	3.1	04/02/2025	mg/dL	2.8-4.1

Sedimentation Rate-Westergren

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Sedimentation Rate-Westergren [02]	2	14	04/02/2025	mm/hr	0-30

Bilirubin, Direct

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Bilirubin, Direct [02]	0.26	0.20	04/02/2025	mg/dL	0.00-0.40

Magnesium

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Magnesium [02]	2.2	**2.5**	06/02/2025	mg/dL	1.6-2.3

Insulin

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Insulin [02]	7.6	14.6	04/02/2025	uIU/mL	2.6-24.9

Ferritin

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Ferritin [02]	66	50	06/02/2025	ng/mL	30-400

Triiodothyronine (T3), Free

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Triiodothyronine (T3), Free [02]	2.7	3.1	04/02/2025	pg/mL	2.0-4.4

Disclaimer
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend
▲ Out of Reference Range ■ Critical or Alert

©2025 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 800-282-7300

Comments
A: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Performing Labs
01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
02: CB - Labcorp Dublin, 6370 Wilcox Road, Dublin, OH 43016-1269 Dir: Vincent Ricchiuti, PhD
For inquiries, the physician may contact Branch: 800-598-3345 Lab: 800-282-7300

Patient Details
Siddiqui, Khan
630 N MADISON ST, HINSDALE, IL, 60521

Phone: **443-847-5106**
Date of Birth: **07/02/1973**
Age: **52**
Sex: **Male**
Patient ID: **PAT-KDGPQE5XQ4HL**
Alternate Patient ID: **PAT-KDGPQE5XQ4HL**

Physician Details
S CLARK
Clark Family Medicine
1246 Yellowstone Ave Ste A2, Pocatello, ID, 83201

Phone: **208-595-6976**
Account Number: **11009950**
Physician ID: **1093078578**
NPI: **1093078578**

Specimen Details
Specimen ID: **219-180-4213-0**
Control ID: **2028634**
Alternate Control Number: **2028634**
Date Collected: **08/07/2025 1620 Local**
Date Received: **08/07/2025 0000 ET**
Date Entered: **08/07/2025 2108 ET**
Date Reported: **08/16/2025 1508 ET**

©2025 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 800-282-7300

LabCorp
Laboratory Corporation of America

1447 York Court
Burlington, NC 27215
800-788-9223
Medical Director: Sanjai Nagendra, MD

Specimen Number	Patient ID	Account Number	Account Phone	Account Fax
219-180-4213-0	PAT-KDGPQE5XQ4HL	11009950	(208) 595-6976	(208) 595-6976

Patient Last Name	Patient First Name	Account Address
SIDDIQUI	KHAN	Clark Family Medicine 1246 Yellowstone Ave Ste A2 Pocatello, ID 83201

Age	Date of Birth	Sex	Fasting
52	07/02/1973	M	YES

Control Number	NPI
2028634	1093078578

Date Collected	Date Entered	Date and Time Reported	Physician ID & Name	Page Number
08/07/2025	08/07/2025	08/08/2025 07:43 PM ET	1093078578 - CLARK, S	1 of 2

❖ NMR LipoProfile ® test

		Reference Interval[1]				
		Percentile[1]	20th	50th	80th	95th
	nmol/L	Low	Moderate	Borderline High	High	Very High
LDL-P (LDL Particle Number)	**452**	**< 1000**	**1000 - 1299**	**1300 - 1599**	**1600 - 2000**	**> 2000**

1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

❖ Lipids

	mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High
LDL-C (calculated)	**42**	**< 100**	**100 - 129**	**130 - 159**	**160 - 189**	**≥ 190**

HDL-C	Triglycerides	Total Cholesterol
mg/dL	mg/dL	mg/dL
54	**49**	**108**
Desirable ≥ 40	Desirable < 150	Desirable < 200

Historical Reporting

LDL-P

LDL-C

❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

Issued or Pending PATENTS	The NMR LipoProfile ® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030	CLIA Number	34D0655059

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call **800-222-7566**.

© 1995-2015 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 2.00

LabCorp
Laboratory Corporation of America

1447 York Court
Burlington, NC 27215
800-788-9223
Medical Director: Sanjai Nagendra, MD

Specimen Number	Patient ID	Account Number	Account Phone	Account Fax
219-180-4213-0	PAT-KDGPQE5XQ4HL	11009950	(208) 595-6976	(208) 595-6976

Patient Last Name	Patient First Name	Account Address
SIDDIQUI	KHAN	Clark Family Medicine 1246 Yellowstone Ave Ste A2 Pocatello, ID 83201

Age	Date of Birth	Sex	Fasting
52	07/02/1973	M	YES

Control Number	NPI
2028634	1093078578

Date Collected	Date Entered	Date and Time Reported	Physician ID & Name	Page Number
08/07/2025	08/07/2025	08/08/2025 07:43 PM ET	1093078578 - CLARK, S	2 of 2

PARTICLE CONCENTRATION AND SIZE

❖ LDL and HDL Particles



Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

Insulin Resistance Score②③



** The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score has not been cleared by the US Food and Drug Administration.

Clinician Notes

❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalaurova I et al., Metab Syndr Relat Disord 2014; 12:422-9.
③ Mackey RH et al., Diab Care 2015; 38:628-36.

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call **800-222-7566**.

© 1995-2015 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 2.00